<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085381</url>
  </required_header>
  <id_info>
    <org_study_id>4-HPV-1001</org_study_id>
    <nct_id>NCT03085381</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Quadrivalent HPV Recombinant Vaccine</brief_title>
  <official_title>A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Bovax Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Bovax Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus
      (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects
      aged 9-45 years.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic and local adverse events during the period of first dose vaccination to 30 days after last dose of vaccination</measure>
    <time_frame>30 days after last dose of vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>HPV vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV vaccine</intervention_name>
    <arm_group_label>HPV vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy females between, and including, 9 and 45 years of age at the time of enrolment

          -  Be able to provide legal identification for the sake of recruitment

          -  Be able to understand and sign informed consent form prior to enrollment and for
             subjects aged 9-17 years, they and their legal guardian(s) are supposed to understand
             and sign informed consent form together

          -  Subjects who the investigator believes that they can and will comply with the protocol
             requirements

          -  Subject must be not pregnant at the enrollment and agree to use adequate contraceptive
             precautions within 7 months or don't have pregnancy plan

        Exclusion Criteria:

          -  Fever or axillary temperature&gt; 37.0â„ƒ before vaccination

          -  Previous vaccination against HPV, or planned administration/administration of a
             vaccine not foreseen by the study protocol within 30 days preceding first dose of
             vaccine; Planned to take part in other clinical research within 7 months after
             participating this study

          -  Abnormal laboratory tests parameters

          -  Administration of any whole blood, plasma or immunoglobulins products within 3 months
             preceding first vaccination

          -  Interval between administration of the study vaccination and any attenuated live
             vaccine less than 14 days, and other vaccines less than 10 days

          -  History of serious allergic disease requiring medical intervention (such as oral and
             throat swelling, difficulty breathing, hypotension or shock)

          -  History of to adverse event to vaccine, or allergic to some food or drug

          -  History of epilepsy, seizures or convulsions, or family history of mental illness

          -  Subjects are immunocompromised or have been diagnosed as suffering from congenital or
             acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus
             erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation
             (JRA), inflammatory bowel disease or other autoimmune diseases, administration of
             immunosuppressants with six months prior to the first vaccine dose.

          -  Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy

          -  Subject to severe hepatorenal disease, cardiovascular disease, hypertension, diabetes,
             malignant tumor, all kinds of infectious diseases and acute illness, or during chronic
             disease acute attack period

          -  Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency,
             coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder

          -  During menstrual period or acute disease period of onset

          -  Breastfeeding, pregnancy (including pregnancy test positive), or planned to be
             pregnant within 7 months

          -  Abnormal cervical cancer screening or subject to CIN or acuteness wet wart that
             relevant to HPV infection in the past two years

          -  Planned to moveout of local before the end of the study or leave the local for a long
             time during the study period

          -  Other unsuitable factors for the study judged by investigators
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaojun Mo, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liu Zhou Centre for Disease Control and Prevention</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2017</study_first_submitted>
  <study_first_submitted_qc>March 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>March 19, 2017</last_update_submitted>
  <last_update_submitted_qc>March 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

